Posted by Michael Wonder on 13 Dec 2022
Enhertu supplemental new drug application submitted in Japan for patients with HER2 mutant metastatic non-small-cell lung cancer
13 December 2022 - Submission based on DESTINY-Lung02 and DESTINY-Lung01 results where Enhertu demonstrated clinically meaningful tumour responses.
Daiichi Sankyo today announced that it has submitted a supplemental new drug application to Japan’s MHLW for Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with previously treated HER2 mutant unresectable advanced or recurrent non-small-cell lung cancer.
